Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Chapel Down earnings drop, but 'strong' sales growth expected

(Sharecast News) - English wine producer Chapel Down saw a big drop in profits in 2024 due to falling revenues and a fair value adjustment on biological produce, but said it expects "strong" sales growth in 2025. The Kent-based company, which had already released sales figures for the year back in January, reported adjusted EBITDA of £2.4m for the 12 months to 31 December, down 58% on the year before.

The decline was mainly due to a £2.7m hit from an accounting adjustment for 'viticultural profit'. The fair value movement is a non-cash adjustment, calculated as the estimated market value of grapes harvested, less the vintage's growing costs, the company explained.

Net sales revenues totalled £16.4m in 2024, down 5% on the year before, but fourth-quarter sales were up 7% year-on-year.

When excluding the now-exited spirits business, fourth-quarter revenues would have been 10% higher than last year, and this positive momentum is said to have carried into the new year.

Stocks grew 18% over the year to £26.6m as a result of an "exceptional" harvest in 2023, which are expected to underpin future sales growth.

However, increased stock levels and the additional planting of 122 acres of new vines has resulted in net debt surging to £9.2m by year-end, up from £1.2m at the end of 2023. Nevertheless, the company said it retains significant headroom on its £20m revolving credit facility.

Chapel Down also announced a new agreement with Jackson Family Wines for the distribution of sparkling wines into the US, effective from mid-Q2.

The US is the company's largest potential export market, but in announcing the deal on Thursday it didn't predict how newly imposed trade tariffs on US imports would affect sales.

In an outlook statement, Chapel Down said: "The consumer environment remains uncertain, but Chapel Down is currently trading well ahead of prior year and expects strong sales growth for the year, with a return to full profitability."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.